ArticleAnnals of hepato-biliary-pancreatic surgery2025
Updates on incidence, mortality and survival of liver cancer using Korea central cancer registry database: 1999-2022.
Article in Annals of hepato-biliary-pancreatic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends and disparities in intrahepatic cholangiocarcinoma mortality in the United States, 1999-2024: a CDC WONDER analysis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds/Aims: Liver cancer (LC) remains a major contributor to morbidity and mortality globally. This study seeks to provide updated insights into the epidemiological trends of LC in South Korea by examining changes in incidence, mortality, and survival rates between 1999 and 2022, with the goal of guiding public health interventions and informing clinical decision-making. Methods: This retrospective cohort study utilized data from Korea Central Cancer Registry (KCCR) for primary LC cases, classified as code C22 according to the International Classification of Diseases, tenth version (ICD-10), diagnosed from 1999 to 2022. Crude rates and age-standardized rates (ASRs) were determined. Additionally, subgroup analyses were conducted separately for hepatocellular carcinoma (HCC, C22.0) and intrahepatic cholangiocarcinoma (IHCC, C22.1). Results: Between 1999 and 2022, both the incidence and mortality rates of HCC showed marked decreases. The annual percent change of ASR for incidence and mortality was -2.99% and -4.89%, respectively. There was a notable rise in 5-year survival rates for HCC, especially among patients with localized-stage disease. Conversely, IHCC incidence stabilized and mortality rates showed minimal change. Although patients with localized IHCC achieved significantly higher survival rates following surgical resection, only a small proportion of IHCC cases were diagnosed at a localized stage (22.4%). Conclusions: Analysis of LC trends in Korea reveals a persistent reduction in incidence and significant improvements in early detection and survival rates for HCC. Despite these gains, IHCC continues to pose clinical difficulties, underscoring the need for further studies to enhance early diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.